专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明申请

US20140349970A1 NOVEL TRICYCLIC COMPOUNDS 审中-公开
标题翻译：新型三聚体化合物
公开(公告)号：US20140349970A1
公开(公告)日：2014-11-27
申请号：US14299652
申请日：2014-06-09
申请人： Neil Wishart , Maria A. Argiriadi , Eric C. Breinlinger , David J. Calderwood , Anna M. Ericsson , Bryan A. Fiamengo , Kristine E. Frank , Michael Friedman , Dawn M. George , Eric R. Goedken , Michael Z. Hoemann , Nathan S. Josephsohn , Biqin C. Li , Michael J. Morytko , Kelly D. Mullen , Gagandeep Somal , Kent D. Stewart , Jeffrey W. Voss , Grier A. Wallace , Lu Wang , Kevin R. Woller
发明人： Neil Wishart , Maria A. Argiriadi , Eric C. Breinlinger , David J. Calderwood , Anna M. Ericsson , Bryan A. Fiamengo , Kristine E. Frank , Michael Friedman , Dawn M. George , Eric R. Goedken , Michael Z. Hoemann , Nathan S. Josephsohn , Biqin C. Li , Michael J. Morytko , Kelly D. Mullen , Gagandeep Somal , Kent D. Stewart , Jeffrey W. Voss , Grier A. Wallace , Lu Wang , Kevin R. Woller
IPC分类号： C07F9/06 , C07D487/14 , C07D471/14
CPC分类号： C07F9/06 , C07D471/14 , C07D487/14 , C07D498/14 , C07D513/14
摘要： The invention provides a compound of Formula (Ia), (Ib), (Ic), (Id), (Ie), (If), (Ig), (Ih), (Ii), (Ij), (Ik), or (Il) as defined herein, pharmaceutically acceptable salts, pro-drugs, biologically active metabolites, stereoisomers and isomers thereof wherein the variable are defined herein. The compounds of the invention are useful for treating immunological and oncological conditions.
摘要翻译：本发明提供了式（Ia），（Ib），（Ic），（Id），（Ie），（If），（Ig），（Ih），（Ii），（Ij），（Ik），或（II），其药学上可接受的盐，前药，生物活性代谢物，立体异构体和异构体，其中变量在本文中定义。本发明的化合物可用于治疗免疫学和肿瘤学病症。

2. 发明申请

US20130216497A1 NOVEL TRICYCLIC COMPOUNDS 审中-公开
标题翻译：新型三聚体化合物
公开(公告)号：US20130216497A1
公开(公告)日：2013-08-22
申请号：US13761501
申请日：2013-02-07
申请人： Neil Wishart , Maria A. Argiriadi , David J. Calderwood , Anna M. Ericsson , Bryan A. Fiamengo , Kristine E. Frank , Michael Friedman , Dawn M. George , Eric R. Goedken , Nathan S. Josephsohn , Biqin C. Li , Michael J. Morytko , Kent D. Stewart , Jeffrey W. Voss , Grier A. Wallace , Lu Wang , Kevin R. Woller
发明人： Neil Wishart , Maria A. Argiriadi , David J. Calderwood , Anna M. Ericsson , Bryan A. Fiamengo , Kristine E. Frank , Michael Friedman , Dawn M. George , Eric R. Goedken , Nathan S. Josephsohn , Biqin C. Li , Michael J. Morytko , Kent D. Stewart , Jeffrey W. Voss , Grier A. Wallace , Lu Wang , Kevin R. Woller
IPC分类号： C07D487/14 , A61K45/06 , A61K31/437 , A61K31/4985 , C07D471/14
CPC分类号： C07D487/14 , A61K31/437 , A61K31/4985 , A61K45/06 , C07D471/14 , C07D498/14 , C07D513/14
摘要： The invention provides compounds of Formula (I) and Formula (II) pharmaceutically acceptable salts, pro-drugs, biologically active metabolites, stereoisomers and isomers thereof wherein the variable are defined herein. The compounds of the invention are useful for treating immunological and oncological conditions.
摘要翻译：本发明提供式（I）和式（II）化合物的药学上可接受的盐，前药，生物活性代谢物，立体异构体和异构体，其中变量在本文中定义。本发明的化合物可用于治疗免疫学和肿瘤学病症。

3. 发明申请

US20090312338A1 Novel Tricyclic Compounds 有权
标题翻译：新型三环化合物
公开(公告)号：US20090312338A1
公开(公告)日：2009-12-17
申请号：US12481028
申请日：2009-06-09
申请人： Neil Wishart , Maria A. Argiriadi , David J. Calderwood , Anna M. Ericsson , Bryan A. Fiamengo , Kristine E. Frank , Michael Friedman , Dawn M. George , Eric R. Goedken , Nathan S. Josephsohn , Biqin C. Li , Michael J. Morytko , Kent D. Stewart , Jeffrey W. Voss , Grier A. Wallace , Lu Wang , Kevin R. Woller
发明人： Neil Wishart , Maria A. Argiriadi , David J. Calderwood , Anna M. Ericsson , Bryan A. Fiamengo , Kristine E. Frank , Michael Friedman , Dawn M. George , Eric R. Goedken , Nathan S. Josephsohn , Biqin C. Li , Michael J. Morytko , Kent D. Stewart , Jeffrey W. Voss , Grier A. Wallace , Lu Wang , Kevin R. Woller
IPC分类号： A61K31/4985 , C07D487/14
CPC分类号： C07D487/14 , C07D498/14 , C07D513/14
摘要： The invention provides a compound of Formula (I) pharmaceutically acceptable salts, pro-drugs, biologically active metabolites, stereoisomers and isomers thereof wherein the variable are defined herein. The compounds of the invention are useful for treating immunological and oncological conditions.
摘要翻译：本发明提供式（I）化合物的药学上可接受的盐，前药，生物活性代谢物，立体异构体和异构体，其中变量在本文中定义。本发明的化合物可用于治疗免疫学和肿瘤学病症。

4. 发明申请

US20110190489A1 Novel Tricyclic Compounds 有权
标题翻译：新型三环化合物
公开(公告)号：US20110190489A1
公开(公告)日：2011-08-04
申请号：US12958291
申请日：2010-12-01
申请人： Neil Wishart , Maria A. Argiriadi , David J. Calderwood , Anna M. Ericsson , Bryan R. Fiamengo , Kristine E. Frank , Michael Friedman , Dawn M. George , Eric R. Goedken , Nathan S. Josephsohn , Biqin C. Li , Michael J. Morytko , Kent D. Stewart , Jeffrey W. Voss , Grier A. Wallace , Lu Wang , Kevin R. Woller , Eric C. Breinlinger , Kelly D. Mullen , Gagandeep Somal
发明人： Neil Wishart , Maria A. Argiriadi , David J. Calderwood , Anna M. Ericsson , Bryan R. Fiamengo , Kristine E. Frank , Michael Friedman , Dawn M. George , Eric R. Goedken , Nathan S. Josephsohn , Biqin C. Li , Michael J. Morytko , Kent D. Stewart , Jeffrey W. Voss , Grier A. Wallace , Lu Wang , Kevin R. Woller , Eric C. Breinlinger , Kelly D. Mullen , Gagandeep Somal
IPC分类号： C07D413/14 , C07D471/14 , C07D487/14 , C07F9/06
CPC分类号： C07F9/06 , C07D471/14 , C07D487/14 , C07D498/14 , C07D513/14
摘要： The invention provides a compound of Formula (Ia), (Ib), (Ic), (Id), (Ie), (If), (Ig), (Ih), (Ii), (Ij), (Ik), or (Il) as defined herein, pharmaceutically acceptable salts, pro-drugs, biologically active metabolites, stereoisomers and isomers thereof wherein the variable are defined herein. The compounds of the invention are useful for treating immunological and oncological conditions.
摘要翻译：本发明提供了式（Ia），（Ib），（Ic），（Id），（Ie），（If），（Ig），（Ih），（Ii），（Ij），（Ik），或（II），其药学上可接受的盐，前药，生物活性代谢物，立体异构体和异构体，其中变量在本文中定义。本发明的化合物可用于治疗免疫学和肿瘤学病症。

5. 发明授权

US07968684B2 IL-18 binding proteins 有权
标题翻译： IL-18结合蛋白
公开(公告)号：US07968684B2
公开(公告)日：2011-06-28
申请号：US10988360
申请日：2004-11-12
申请人： Tariq Ghayur , Boris Labkovsky , Jeffrey W. Voss , Larry Green , John Babcook , Xiao-chi Jia , James Wieler , Jaspal Singh Kang , Brad Hedberg
发明人： Tariq Ghayur , Boris Labkovsky , Jeffrey W. Voss , Larry Green , John Babcook , Xiao-chi Jia , James Wieler , Jaspal Singh Kang , Brad Hedberg
IPC分类号： C07K16/00 , A61K39/395 , C12N1/11 , C12N1/15 , C12N1/21 , C12N5/04 , C12N5/07 , C12N15/09 , C12N15/11 , C12N15/13 , C12N15/63
CPC分类号： C07K16/244 , A61K2039/505 , C07H21/04 , C07K2317/21
摘要： The present invention encompasses IL-18 binding proteins, particularly antibodies that bind human interleukin-18 (hIL-18). Specifically, the invention relates to antibodies that are entirely human antibodies. Preferred antibodies have high affinity for hIL-18 and/or that neutralize hIL-18 activity in vitro and in vivo. An antibody of the invention can be a full-length antibody or an antigen-binding portion thereof. Method of making and method of using the antibodies of the invention are also provided. The antibodies, or antibody portions, of the invention are useful for detecting hIL-18 and for inhibiting hIL-18 activity, e.g., in a human subject suffering from a disorder in which hIL-18 activity is detrimental.
摘要翻译：本发明包括IL-18结合蛋白，特别是结合人白细胞介素-18（hIL-18）的抗体。具体地，本发明涉及完全是人抗体的抗体。优选的抗体对hIL-18具有高亲和力和/或在体外和体内中和hIL-18活性。本发明的抗体可以是全长抗体或其抗原结合部分。还提供了制备方法和使用本发明抗体的方法。本发明的抗体或抗体部分可用于检测hIL-18和抑制hIL-18活性，例如在患有hIL-18活性有害的病症的人类受试者中。

6. 发明授权

US5700640A Inducers of gamma globin gene expression and screening assays therefor 失效
标题翻译： γ球蛋白基因表达的诱导剂及其筛选试验
公开(公告)号：US5700640A
公开(公告)日：1997-12-23
申请号：US308461
申请日：1994-09-16
申请人： Jeffrey W. Voss , Connie Caron
发明人： Jeffrey W. Voss , Connie Caron
IPC分类号： A61K31/19 , C12Q1/68
CPC分类号： A61K31/19 , C12Q1/6897
摘要： Methods for stimulating gamma globin gene expression in a mammalian cell comprising contacting the cell with a compound selected from valeric acid and certain isomers, derivatives or salts thereof, including isovaleric acid, 4-pentynoic acid and methylthioacetic acid, or an inhibitor of a short chain fatty acyl CoA dehydrogenase, or an activator of protein kinase C are disclosed. The methods of the invention are particularly useful for ameliorating .beta.-globin disorders, such as sickle cell anemia or .beta.-thalassemia. The method of the invention can also be used to prevent or ameliorate malaria in a mammal. The compounds of the invention can also be used to stimulate differentiation of a cell. Pharmaceutical compositions of the active compounds of the invention are also disclosed. Screening assays for identifying agents that stimulate gamma globin gene expression in an erythroid cell, stimulate cell differentiation or stimulate transport of a short chain fatty acid, or derivative or salt thereof, into cells are also disclosed.
摘要翻译：用于刺激哺乳动物细胞中的γ珠蛋白基因表达的方法，包括使细胞与选自戊酸和某些异构体，其衍生物或其盐的化合物，包括异戊酸，4-戊炔酸和甲基硫代乙酸或短链的抑制剂接触脂肪酰辅酶A脱氢酶或蛋白激酶C的活化剂。本发明的方法特别可用于改善β-球蛋白病症，例如镰状细胞性贫血或β-地贫。本发明的方法也可用于预防或改善哺乳动物的疟疾。本发明的化合物也可用于刺激细胞的分化。还公开了本发明的活性化合物的药物组合物。还公开了用于鉴定刺激红细胞中的γ珠蛋白基因表达，刺激细胞分化或刺激短链脂肪酸或其衍生物或其盐转运到细胞中的药剂的筛选试验。

7. 发明申请

US20110311474A1 Novel Tricyclic Compounds 有权
标题翻译：新型三环化合物
公开(公告)号：US20110311474A1
公开(公告)日：2011-12-22
申请号：US12958115
申请日：2010-12-01
申请人： Neil WISHART , Maria A. ARGIRIADI , David J. CALDERWOOD , Anna M. ERICSSON , Bryan R. FIAMENGO , Kristine E. FRANK , Michael FRIEDMAN , Dawn M. GEORGE , Eric R. GOEDKEN , Nathan S. JOSEPHSOHN , Biqin C. LI , Michael J. MORYTKO , Kent D. STEWART , Jeffrey W. VOSS , Grier A. WALLACE , Lu WANG , Kevin R. WOLLER
发明人： Neil WISHART , Maria A. ARGIRIADI , David J. CALDERWOOD , Anna M. ERICSSON , Bryan R. FIAMENGO , Kristine E. FRANK , Michael FRIEDMAN , Dawn M. GEORGE , Eric R. GOEDKEN , Nathan S. JOSEPHSOHN , Biqin C. LI , Michael J. MORYTKO , Kent D. STEWART , Jeffrey W. VOSS , Grier A. WALLACE , Lu WANG , Kevin R. WOLLER
IPC分类号： A61K31/4985 , C07D471/14 , A61K31/437 , A61K39/395 , A61P25/00 , A61K38/21 , A61K38/18 , A61K31/573 , A61P35/00 , A61P37/06 , C07D487/14 , A61K38/20
CPC分类号： C07D487/14 , A61K31/437 , A61K31/4985 , A61K45/06 , C07D471/14 , C07D498/14 , C07D513/14
摘要： The invention provides compounds of Formula (I) and Formula (II) pharmaceutically acceptable salts, pro-drugs, biologically active metabolites, stereoisomers and isomers thereof wherein the variable are defined herein. The compounds of the invention are useful for treating immunological and oncological conditions.
摘要翻译：本发明提供式（I）和式（II）化合物的药学上可接受的盐，前药，生物活性代谢物，立体异构体和异构体，其中变量在本文中定义。本发明的化合物可用于治疗免疫学和肿瘤学病症。

8. 发明申请

US20100291088A1 IL-18 BINDING PROTEINS 有权
标题翻译： IL-18结合蛋白
公开(公告)号：US20100291088A1
公开(公告)日：2010-11-18
申请号：US12843740
申请日：2010-07-26
申请人： Tariq Ghayur , Boris Labkovsky , Jeffrey W. Voss , Larry Green , John Babcook , Xiao-chi Jia , James Wieler , Jaspal Singh Kang , Brad Hedberg
发明人： Tariq Ghayur , Boris Labkovsky , Jeffrey W. Voss , Larry Green , John Babcook , Xiao-chi Jia , James Wieler , Jaspal Singh Kang , Brad Hedberg
IPC分类号： A61K39/395 , C07H21/04 , C12N15/63 , C12N1/00 , C12N1/21 , C12N5/10 , C12N1/15 , C12N1/19 , C12P21/02 , A61K38/17 , C07K16/24 , A61P29/00
CPC分类号： C07K16/244 , A61K2039/505 , C07H21/04 , C07K2317/21
摘要： The present invention encompasses IL-18 binding proteins, particularly antibodies that bind human interleukin-18 (hIL-18). Specifically, the invention relates to antibodies that are entirely human antibodies. Preferred antibodies have high affinity for hIL-18 and/or that neutralize hIL-18 activity in vitro and in vivo. An antibody of the invention can be a full-length antibody or an antigen-binding portion thereof. Method of making and method of using the antibodies of the invention are also provided. The antibodies, or antibody portions, of the invention are useful for detecting hIL-18 and for inhibiting hIL-18 activity, e.g., in a human subject suffering from a disorder in which hIL-18 activity is detrimental.
摘要翻译：本发明包括IL-18结合蛋白，特别是结合人白细胞介素-18（hIL-18）的抗体。具体地，本发明涉及完全是人抗体的抗体。优选的抗体对hIL-18具有高亲和力和/或在体外和体内中和hIL-18活性。本发明的抗体可以是全长抗体或其抗原结合部分。还提供了制备方法和使用本发明抗体的方法。本发明的抗体或抗体部分可用于检测hIL-18和抑制hIL-18活性，例如在患有hIL-18活性有害的病症的人类受试者中。

9. 发明授权

US06783756B2 Methods for regulating gene expression 失效
标题翻译：调节基因表达的方法
公开(公告)号：US06783756B2
公开(公告)日：2004-08-31
申请号：US09281674
申请日：1999-03-30
申请人： Hermann Bujard , Manfred Gossen , Jochen G. Salfeld , Jeffrey W. Voss
发明人： Hermann Bujard , Manfred Gossen , Jochen G. Salfeld , Jeffrey W. Voss
IPC分类号： A61K6300
CPC分类号： C12N15/62 , A01K67/0275 , A01K2217/05 , A01K2217/075 , C07K2319/09 , C07K2319/61 , C07K2319/71 , C07K2319/80 , C12N15/635 , C12N15/85 , C12N2830/006
摘要： A method for regulating expression of a tet operator-linked gene in a cell of a subject is disclosed. In one embodiment, the method involves introducing into the cell a nucleic acid molecule encoding a tetracycline-controllable transactivator (tTA), the tTA comprising a Tet repressor operably linked to a polypeptide which directly or indirectly activates transcription in eucaryotic cells; and modulating the concentration of a tetracycline, or analogue thereof, in the subject. Alternatively, in another embodiment, the method involves obtaining the cell from the subject, introducing into the cell a first nucleic acid molecule which operatively links a gene to at least one tet operator sequence, introducing into the cell a second nucleic acid molecule encoding a tTA, to form a modified cell, administering the modified cell to the subject, and modulating the concentration of a tetracycline, or analogue thereof, in the subject. The first and second nucleic acid molecule can be within a single molecule (e.g., in the same vector) or on separate molecules.
摘要翻译：公开了一种用于调节受试者细胞中tet操纵子连接基因表达的方法。在一个实施方案中，所述方法包括将编码四环素可控反式激活因子（tTA）的核酸分子引入细胞，所述tTA包含可操作地连接到直接或间接激活真核细胞中的转录的多肽的Tet阻遏物; 并调节受试者中四环素或其类似物的浓度。或者，在另一个实施方案中，所述方法包括从受试者获得细胞，向细胞中引入第一核酸分子，该第一核酸分子可操作地将基因连接至至少一个tet操纵子序列，将编码tTA的第二核酸分子，以形成修饰的细胞，向受试者施用修饰的细胞，并调节受试者中四环素或其类似物的浓度。第一和第二核酸分子可以在单分子内（例如，在同一载体中）或分开的分子上。

10. 发明授权

US06252136B1 Transgenic organisms having tetracycline-regulated transcriptional regulatory systems 有权
标题翻译：具有四环素调节转录调控系统的转基因生物
公开(公告)号：US06252136B1
公开(公告)日：2001-06-26
申请号：US09163269
申请日：1998-09-29
申请人： Hermann Bujard , Manfred Gossen , Jochen G. Salfeld , Jeffrey W. Voss
发明人： Hermann Bujard , Manfred Gossen , Jochen G. Salfeld , Jeffrey W. Voss
IPC分类号： C12N1509
CPC分类号： C12N15/62 , A01K67/0275 , A01K2217/05 , A01K2217/075 , C07K2319/09 , C07K2319/61 , C07K2319/71 , C07K2319/80 , C12N15/635 , C12N15/85 , C12N2830/006
摘要： Transgenic animals carrying two transgenes, the first coding for a transactivator fusion protein comprising a tet repressor and a polypeptide which directly or indirectly activates in eucaryotic cells, and the second comprising a gene operably linked to a minimal promoter operably linked to at least one tet operator sequence, are disclosed. Isolated DNA molecules (e.g., targeting vectors) for integrating a polynucleotide sequence encoding a transactivator of the invention at a predetermined location within a second target DNA molecule by homologous recombination are also disclosed. Transgenic animals having the DNA molecules of the invention integrated at a predetermined location in a chromosome by homologous recombination are also encompassed by the invention. Methods to regulate the expression of a tet operator linked-gene of interest by administering tetracycline or a tetracycline analogue to an animal of the invention are also disclosed. The regulatory system of the invention allows for conditional inactivation or modulation of expression of a gene of interest in a host cell or animal.
摘要翻译：携带两个转基因的转基因动物，第一编码包含直接或间接在真核细胞中活化的tet阻遏物和多肽的反式激活因子融合蛋白，第二编码包含与可操作地连接至少一个tet操纵子的最小启动子可操作地连接的基因序列。还公开了通过同源重组将编码本发明的反式激活物的多核苷酸序列整合到第二靶DNA分子内的预定位置的分离的DNA分子（例如靶向载体）。通过同源重组将具有整合在染色体中预定位置的本发明的DNA分子的转基因动物也包括在本发明中。还公开了通过向本发明的动物施用四环素或四环素类似物来调节所述目的基因的表达的方法。本发明的调节系统允许在宿主细胞或动物中有条件地失活或调控感兴趣的基因的表达。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式